{"id":391156,"date":"2016-04-19T00:00:00","date_gmt":"2016-04-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0005-2016-biopharma-non-small-cell-lung-cancer-current-treatment-us-2016\/"},"modified":"2026-03-31T09:02:19","modified_gmt":"2026-03-31T09:02:19","slug":"cutron0005-2016-biopharma-non-small-cell-lung-cancer-current-treatment-us-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0005-2016-biopharma-non-small-cell-lung-cancer-current-treatment-us-2016\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Current Treatment | US | 2016"},"content":{"rendered":"<p>Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-defined patient populations and the FDA\u2019s approval of several targeted therapies in 2015 have positioned NSCLC at the forefront of personalized medicine in oncology and resulted in an evolving treatment landscape for the disease. This analysis provides insight on current use of approved therapies for NSCLC in the United States and on oncologists\u2019 perception of these therapies.<\/p>\n","protected":false},"template":"","class_list":["post-391156","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391156\/revisions"}],"predecessor-version":[{"id":394279,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391156\/revisions\/394279"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}